Inhaled corticosteroid use and associated outcomes in elderly patients with moderate to severe chronic pulmonary disease
References (31)
- et al.
Epidemiology of asthmam, allergic rhinitis in a total community, Tecumseh MI. 3. Second survey of community
J Allergy Clin Immunol.
(1974) Disease management of COPD with pulmonary rehabilitation
Chest.
(1997)Predictors of medication adherence in the elderly
Clin Ther.
(1998)- et al.
Effectiveness of steroid therapy in acute exacerbations of asthma: A meta-analysis
Am J Emerg Med.
(1992) - et al.
Changes in asthma severity in Manitoba
Chest.
(1995) - et al.
A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation
J Chronic Dis.
(1987) - et al.
Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases
J Clin Epidemiol.
(1992) - et al.
Medication, chronic illness and identity: The perspective of people with asthma
Soc Sci Med.
(1997) - et al.
Surveillance for asthma—United States, 1960 –1995
MMWR CDC Surveill Summ.
(1998) - et al.
The prevalence and incidence of asthma and asthma-like symptoms in a general population sample
Am Rev Respir Dis.
(1980)
Asthma in the elderly: An epidemiological survey
Br Med J.
Respiratory symptoms among elderly people in the New Forest area assessed by a postal questionnaire
Age Ageing.
Asthma in the elderly
Br J Hosp Med.
Introduction
A national estimate of economic costs of asthma
Am J Respir Crit Care Med.
Cited by (49)
The Impact of Inhaler Device Regimen in Patients with Asthma or COPD
2021, Journal of Allergy and Clinical Immunology: In PracticeCitation Excerpt :Poor adherence leads to negative clinical consequences, which may have an economic impact, as shown in a retrospective study of patients aged 65 years and older with moderate-to-severe asthma, COPD, chronic bronchitis, chronic airway obstruction, or emphysema, who were treated with inhaled corticosteroids. Poorer medication adherence was associated with a significant increase in total annual physician visits, and better adherence was associated with a significant decrease in the number of annual hospitalizations.38 Studies suggest that inhaler device and preference can influence adherence, persistence, or both.23,24,35,36,39
Structured pharmacist-led intervention programme to improve medication adherence in COPD patients: A randomized controlled study
2018, Research in Social and Administrative PharmacyCitation Excerpt :Non-adherence with their treatment recommendations can be both intentional (such as, negative attitudes to medication-taking behavior, side effects, cost, does not feel sick, etc.) and unintentional, due to reasons related to forgetting, misunderstanding, problems in remembering, failure to plan ahead, etc.16 In addition, there are concerns with inhaler technique, which is typically seen as sub-optimal2,17 with adherence adversely affected if patients are using different devices requiring different techniques.18 However, it is evident that better medication adherence is associated with a decrease in the number of emergency department visits and length of hospital stay among patients with chronic respiratory diseases19 with improved adherence reducing costs.20 Consequently, in order for a medication to be useful, not only should the active ingredient be effective, and its delivery must be optimal, but also patients' adherence to their medications is an essential factor for success of therapy.6
Cost-Utility Analysis of Long-Acting Beta Agonists versus Leukotriene Receptor Antagonists in Older Adults with Persistent Asthma Receiving Concomitant Inhaled Corticosteroid Therapy
2016, Value in HealthCitation Excerpt :We did not calculate asthma hospitalization rate for ICS-only patients using Medicare data to avoid the potential confounding by asthma severity because those treated by ICS monotherapy usually have less severe asthma. Instead, we used historical data [49] to extract asthma event rates in patients treated with ICS alone before the widespread use of the add-on treatments. Although there might be some discrepancy between the Medicare cohort and the historical cohort, the focus of this study was to compare the two add-on treatments, which should not be affected by this possible discrepancy.
Safety and efficacy of the once-daily anticholinergic BEA2180 compared with tiotropium in patients with COPD
2013, Respiratory MedicineCitation Excerpt :None of the events leading to death were considered to be related to study medication and the causes of death were consistent with those expected in a patient population of >10 pack-year smokers. Therapeutic delivery is a key concern of COPD maintenance treatment, given issues of device use and compliance.2,19 In many countries, tiotropium is administered via the Respimat® SMI, a novel propellant-free inhaler with a soft-mist aerosol delivering fine-particle fraction.
Methods to assess COPD medications adherence in healthcare databases: a systematic review
2023, European Respiratory Review